Subscribe to RSS
DOI: 10.1055/a-1970-3166
Lichen Planus After Denosumab
Lichen planus nach Denosumab
Abstract
Lichenoid reactions have been described as a side effect of several drugs. Here we describe the development of lichen planus (LP) of the mammilla following off-label use of denosumab in an adolescent patient with mono-ostotic fibrous dysplasia. Lichen planus is considered an autoimmune disorder. Since receptor activator of nuclear factor κΒ ligand (RANKL), the target of denosumab action, has regulatory function in the immune system, it is feasible, that LP may be caused as part of an immunological dysregulation.
Zusammenfassung
Lichenoide Reaktionen sind als Nebenwirkung unterschiedlicher Medikamente beschrieben. Wir berichten die Entwicklung von Lichen planus (LP) der Brustwarze bei einem jugendlichen Patienten mit mono-ostotischer Fibröser Dysplasie der off-label mit Denosumab behandelt wurde. Für den Lichen planus wird eine auto-immunologische Genese angenommen. Da receptor activator of nuclear factor κΒ ligand (RANKL), als Zielstruktur von Denosumab, regulatorische Funktionen im Immunsystem hat, ist die Induktion einer autoimmunologischen Genese denkbar.
Publication History
Received: 24 March 2022
Accepted: 28 October 2022
Article published online:
28 February 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342 DOI: 10.1038/nature01658.
- 2 Polyzos SA, Makras P, Tournis S, Anastasilakis AD. Off-label uses of denosumab in metabolic bone diseases. Bone 2019; 129: 115048 DOI: 10.1016/j.bone.2019.115048.
- 3 Boyce AM, Chong WH, Yao J. et al. Denosumab treatment for fibrous dysplasia. Journal of Bone and Mineral Research 2012; 27: 1462-1470 DOI: 10.1002/jbmr.1603.
- 4 Höppner J, Steff K, Lobert F, Heyer CM, Hauffa BP, Grasemann C. Rhizomelia and Impaired Linear Growth in a Girl with Juvenile Paget Disease: The Natural History of the Condition. Hormone Research in Paediatrics. Published online 2021; DOI: 10.1159/000517164.
- 5 Huzum B, Antoniu S, Dragomir R. Treatment of fibrous dysplasia: focus on denosumab. Expert Opinion on Biological Therapy 2022; 22: 397-405 DOI: 10.1080/14712598.2022.2022118.
- 6 Meier ME, van der Bruggen W, van de Sande MAJ, Appelman-Dijkstra NM. Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases. Bone Reports 2021; 14 April 101058 DOI: 10.1016/j.bonr.2021.101058.
- 7 Cachia M, Betts A, Aquilina S. Denosumab and lichen planus: two cases. Clinical and Experimental Dermatology 2021; 46: 356-357 DOI: 10.1111/ced.14378.
- 8 King BJ, Lehman JS, Sartori Valinotti JC. Denosumab-induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings. Journal of Cutaneous Pathology 2018; 45: 156-158 DOI: 10.1111/cup.13070.
- 9 WHO Pharmaceuticals Newsletter – N°6, 2016. Accessed June 22, 2022 https://www.who.int/publications/i/item/WPN-2016-06
- 10 Lyakhovitsky A, Oshinsky S, Gilboa S, Barzilai A. Alopecia areata after denosumab treatment for osteoporosis. JAAD Case Rep 2016; 2: 298-300 DOI: 10.1016/j.jdcr.2016.06.003.
- 11 Dourra M, Mussad S, Qiblawi S, Singer R. Denosumab-induced alopecia areata with lichenoid eruption. JAAD Case Rep 2021; 17: 9-11 DOI: 10.1016/j.jdcr.2021.09.003.